S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Is Salesforce Stock a Bargain Down Here?
Tesla Shares Are Sliding, Here’s Why
China Threat Triggers Potential Mining Boom for Investors (Ad)
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Lockheed teams with Israel's Rafael on laser defense
China Threat Triggers Potential Mining Boom for Investors (Ad)
Russian oil price cap, EU ban aim to limit Kremlin war chest
World Cup fans find booze at hotels, Qatar's 1 liquor store
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Is Salesforce Stock a Bargain Down Here?
Tesla Shares Are Sliding, Here’s Why
China Threat Triggers Potential Mining Boom for Investors (Ad)
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Lockheed teams with Israel's Rafael on laser defense
China Threat Triggers Potential Mining Boom for Investors (Ad)
Russian oil price cap, EU ban aim to limit Kremlin war chest
World Cup fans find booze at hotels, Qatar's 1 liquor store
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Is Salesforce Stock a Bargain Down Here?
Tesla Shares Are Sliding, Here’s Why
China Threat Triggers Potential Mining Boom for Investors (Ad)
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Lockheed teams with Israel's Rafael on laser defense
China Threat Triggers Potential Mining Boom for Investors (Ad)
Russian oil price cap, EU ban aim to limit Kremlin war chest
World Cup fans find booze at hotels, Qatar's 1 liquor store
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Is Salesforce Stock a Bargain Down Here?
Tesla Shares Are Sliding, Here’s Why
China Threat Triggers Potential Mining Boom for Investors (Ad)
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Lockheed teams with Israel's Rafael on laser defense
China Threat Triggers Potential Mining Boom for Investors (Ad)
Russian oil price cap, EU ban aim to limit Kremlin war chest
World Cup fans find booze at hotels, Qatar's 1 liquor store
NASDAQ:ONVO

Organovo - ONVO Stock Forecast, Price & News

$1.51
-0.01 (-0.66%)
(As of 12/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.48
$1.55
50-Day Range
$1.47
$2.17
52-Week Range
$1.45
$5.20
Volume
12,547 shs
Average Volume
64,865 shs
Market Capitalization
$13.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ONVO stock logo

About Organovo (NASDAQ:ONVO) Stock

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Stock News Headlines

StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)
Organovo Holdings, Inc. (ONVO)
See More Headlines
Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Company Calendar

Last Earnings
8/08/2019
Today
12/06/2022
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONVO
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-11,450,000.00
Pretax Margin
-757.32%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$3.47 per share

Miscellaneous

Free Float
8,364,000
Market Cap
$13.16 million
Optionable
Optionable
Beta
1.02

Key Executives

  • Mr. Keith E. Murphy (Age 50)
    Exec. Chairman
    Comp: $496.77k
  • Dr. Jeffrey N. Miner (Age 60)
    Chief Scientific Officer
    Comp: $303.75k
  • Mr. Thomas Einar Jurgensen J.D. (Age 65)
    MS, Gen. Counsel & Corp. Sec.
    Comp: $548.03k
  • Ms. Vaidehi Joshi (Age 36)
    Director of Discovery Biology & Director
    Comp: $4.42k
  • Mr. Thomas P. Hess CPA (Age 58)
    MBA, Pres & CFO
  • Dr. Curtis M. Tyree Ph.D.
    Sr. VP of Strategy & Bus. Devel.













ONVO Stock - Frequently Asked Questions

How have ONVO shares performed in 2022?

Organovo's stock was trading at $3.63 at the start of the year. Since then, ONVO stock has decreased by 58.4% and is now trading at $1.51.
View the best growth stocks for 2022 here
.

When is Organovo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our ONVO earnings forecast
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) released its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, meeting analysts' consensus estimates of ($1.00). The medical research company earned $0.67 million during the quarter, compared to the consensus estimate of $0.77 million.

When did Organovo's stock split?

Organovo's stock reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.25%), ARK Investment Management LLC (3.16%), Renaissance Technologies LLC (1.38%) and Virtu Financial LLC (0.17%).
View institutional ownership trends
.

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $1.51.

How much money does Organovo make?

Organovo (NASDAQ:ONVO) has a market capitalization of $13.16 million and generates $1.50 million in revenue each year. The medical research company earns $-11,450,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The official website for the company is www.organovo.com. The medical research company can be reached via phone at (858) 224-1000 or via email at ir@organovo.com.

This page (NASDAQ:ONVO) was last updated on 12/6/2022 by MarketBeat.com Staff